Akshat Singhal

Akshat Singhal

Auto-generated profile, based on publicly available information

Akshat Singhal

Department of Computer Science and Engineering, University of California, San Diego, La Jolla, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2020 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
ASAkshat Singhal
Akshat Singhal
SCSong Cao
Song Cao
CCChristopher Churas
Christopher Churas
DPDexter Pratt
Dexter Pratt
SFSanto Fortunato
Santo Fortunato
TITrey Ideker
Trey Ideker
Detection of community structure has become a fundamental step in the analysis of biological networks with application to protein function annotation, disease gene prediction, and drug discovery. This recent impact creates a need to make these techniques and their accompanying visualization schemes available to a broad range of biologists. Here we present a service-oriented, end-to-end software framework, CDAPS (Community Detection APplication and Service), that integrates the identification, annotation, visualization, and interrogation of multiscale network communities, accessible within the popular Cytoscape network analysis platform. With novel design principles, CDAPS addresses unmet new challenges, such as identifying hierarchical community structures, comparison of outputs generated from diverse network resources, and easy deployment of new algorithms, to facilitate community-sourced science. We demonstrate that the CDAPS framework can be applied to high-throughput protein-protein interaction networks to gain novel insights, such as the identification of putative new members of known protein complexes.

5 March 2024 in Nature Cancer
Verified
Journal Article
Open access
PDF file
SPSungjoon Park
Sungjoon Park
ESErica Silva
Erica Silva
ASAkshat Singhal
Akshat Singhal
MKMarcus R. Kelly
Marcus R. Kelly
KLKate Licon
Kate Licon
TITrey Ideker
Trey Ideker
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is) have revolutionized breast cancer therapy. However, <50% of patients have an objective response, and nearly all patients develop resistance during therapy. To elucidate the underlying mechanisms, we constructed an interpretable deep learning model of the response to palbociclib, a CDK4/6i, based on a reference map of multiprotein assemblies in cancer. The model identifies eight core assemblies that integrate rare and common alterations across 90 genes to stratify palbociclib-sensitive versus palbociclib-resistant cell lines. Predictions translate to patients and patient-derived xenografts, whereas single-gene biomarkers do not. Most predictive assemblies can be shown by CRISPR–Cas9 genetic disruption to regulate the CDK4/6i response. Validated assemblies relate to cell-cycle control, growth factor signaling and a histone regulatory complex that we show promotes S-phase entry through the activation of the histone modifiers KAT6A and TBL1XR1 and the transcription factor RUNX1. This study enables an integrated assessment of how a tumor’s genetic profile modulates CDK4/6i resistance.

16 February 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
XZXiaoyu Zhao
Xiaoyu Zhao
ASAkshat Singhal
Akshat Singhal
SPSungjoon Park
Sungjoon Park
JKJungHo Kong
JungHo Kong
RBRobin Bachelder
Robin Bachelder
TITrey Ideker
Trey Ideker
Rapid proliferation is a hallmark of cancer associated with sensitivity to therapeutics that cause DNA replication stress (RS). Many tumors exhibit drug resistance, however, via molecular pathways that are incompletely understood. Here, we develop an ensemble of predictive models that elucidate how cancer mutations impact the response to common RS-inducing (RSi) agents. The models implement recent advances in deep learning to facilitate multidrug prediction and mechanistic interpretation. Initial studies in tumor cells identify 41 molecular assemblies that integrate alterations in hundreds of genes for accurate drug response prediction. These cover roles in transcription, repair, cell-cycle checkpoints, and growth signaling, of which 30 are shown by loss-of-function genetic screens to regulate drug sensitivity or replication restart. The model translates to cisplatin-treated cervical cancer patients, highlighting an RTK–JAK–STAT assembly governing resistance. This study defines a compendium of mechanisms by which mutations affect therapeutic responses, with implications for precision medicine. Significance: Zhao and colleagues use recent advances in machine learning to study the effects of tumor mutations on the response to common therapeutics that cause RS. The resulting predictive models integrate numerous genetic alterations distributed across a constellation of molecular assemblies, facilitating a quantitative and interpretable assessment of drug response. This article is featured in Selected Articles from This Issue, p. 384

15 October 2024 in PNAS Nexus
Verified
Journal Article
Open access
PDF file
RBRegan L Bailey
Regan L Bailey
AMAmanda J MacFarlane
Amanda J MacFarlane
MFMartha Field
Martha Field
ITIlias Tagkopoulos
Ilias Tagkopoulos
SBSergio Baranzini
Sergio Baranzini
PSPatrick J Stover
Patrick J Stover
Science-informed decisions are best guided by the objective synthesis of the totality of evidence around a particular question and assessing its trustworthiness through systematic processes. However, there are major barriers and challenges that limit science-informed food and nutrition policy, practice, and guidance. First, insufficient evidence, primarily due to acquisition cost of generating high-quality data, and the complexity of the diet-disease relationship. Furthermore, the sheer number of systematic reviews needed across the entire agriculture and food value chain, and the cost and time required to conduct them, can delay the translation of science to policy. Artificial intelligence offers the opportunity to (i) better understand the complex etiology of diet-related chronic diseases, (ii) bring more precision to our understanding of the variation among individuals in the diet-chronic disease relationship, (iii) provide new types of computed data related to the efficacy and effectiveness of nutrition/food interventions in health promotion, and (iv) automate the generation of systematic reviews that support timely decisions. These advances include the acquisition and synthesis of heterogeneous and multimodal datasets. This perspective summarizes a meeting convened at the National Academy of Sciences, Engineering, and Medicine. The purpose of the meeting was to examine the current state and future potential of artificial intelligence in generating new types of computed data as well as automating the generation of systematic reviews to support evidence-based food and nutrition policy, practice, and guidance.

6 January 2026 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
PDF file
XWXin Wang
Xin Wang
JNJulia Nguyen
Julia Nguyen
KNKristen Nader
Kristen Nader
MMMitro Miihkinen
Mitro Miihkinen
PWPatrick Wall
Patrick Wall
BHBenjamin Haibe-Kains
Benjamin Haibe-Kains

6 January 2025 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
ASAkshat Singhal
Akshat Singhal
XZXiaoyu Zhao
Xiaoyu Zhao
PWPatrick Wall
Patrick Wall
ESEmily So
Emily So
GCGuido Calderini
Guido Calderini
TITrey Ideker
Trey Ideker
The rapid evolution of machine learning has led to a proliferation of sophisticated models for predicting therapeutic responses in cancer. While many of these show promise in research, standards for clinical evaluation and adoption are lacking. Here, we propose seven hallmarks by which predictive oncology models can be assessed and compared. These are Data Relevance and Actionability, Expressive Architecture, Standardized Benchmarking, Generalizability, Interpretability, Accessibility and Reproducibility, and Fairness. Considerations for each hallmark are discussed along with an example model scorecard. We encourage the broader community, including researchers, clinicians, and regulators, to engage in shaping these guidelines toward a concise set of standards. Significance: As the field of artificial intelligence evolves rapidly, these hallmarks are intended to capture fundamental, complementary concepts necessary for the progress and timely adoption of predictive modeling in precision oncology. Through these hallmarks, we hope to establish standards and guidelines that enable the symbiotic development of artificial intelligence and precision oncology.